• OPEN AN ACCOUNT
Indian Indices
Nifty
25,405.30 -48.10
(-0.19%)
Sensex
83,239.47 -170.22
( -0.20%)
Bank Nifty
56,791.95 -207.25
( -0.36%)
Nifty IT
38,854.30 -24.80
( -0.06%)
Global Indices
Nasdaq
44,498.76 -17.19
(-0.04%)
Dow Jones
6,247.07 28.06
(0.45%)
Hang Seng
39,705.85 -56.63
(-0.14%)
Nikkei 225
8,823.20 48.51
(0.55%)
Forex
USD-INR
85.59 -0.04
(-0.04%)
EUR-INR
100.92 0.38
(0.38%)
GBP-INR
117.62 0.20
(0.17%)
JPY-INR
0.60 0.00
(0.46%)

EQUITY - MARKET SCREENER

Sparc Electrex Ltd
Industry :  Trading
BSE Code
ISIN Demat
Book Value()
531370
INE960B01015
7.5231529
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
0
7.65
EPS(TTM)
Face Value()
Div & Yield %
0
10
0
 

cress&a railway solutions ltd
Alembic Pharma jumps after receiving USFDA nod for Doxorubicin Hydrochloride Injection
Jun 30,2025
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Doxil Liposome Injection, of Baxter Healthcare Corporation. Doxorubicin Hydrochloride Liposome Injection is indicated for the treatment of ovarian cancer, AIDS-related Kaposi’s sarcoma, and multiple myeloma.

According to IQVIA, the estimated market size for Doxorubicin Hydrochloride Liposome Injection single-dose vials is $29 million for the 12 months ending March 2025. Alembic now has a cumulative total of 224 ANDA approvals from the USFDA, including 201 final approvals and 23 tentative approvals.

Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world. Its research and manufacturing facilities are approved by regulatory authorities of many developed countries, including the USFDA.

The company’s consolidated net profit declined 12% to Rs 156.89 crore despite a 16.7% jump in net sales to Rs 1,769.64 crore in Q4 FY25 over Q4 FY24.